Biopharmaceutical services provider expands to European market
Millipore has acquired European-based services provider BioAnaLab, extending the company&39;s biopharmaceutical services business into Europe.
Millipore has acquired European-based services provider BioAnaLab, extending the company's biopharmaceutical services business into Europe.
"Our acquisition of BioAnaLab will allow us to build on our reputation as a trusted outsource partner in North America by establishing a presence in the fast-growing European biotech market," said Jonathan DiVincenzo, president of the company’s bioscience division, in a statement. "BioAnaLab will add cGMP support testing capabilities to our portfolio, a solid customer base and a team of services professionals with expertise in emerging scientific disciplines."
BioAnaLab current offerings include assay transfer/development, validation and sample analysis and vaccine services. Millipore's experience in biomarker analytical services is expected to strengthen BioAnaLab's current offerings in that area.
More information in Millpore can be found at www.millipore.com
and on BioAnaLab at www.bioanalab.com
Pharmaceutical excipients, such as polyethylene glycol-based polymers, must be tested for the presence of ethylene oxide (EtO) and 1,4-dioxane as part of a safety assessment, according to USP Chapter <228>.
AOAC International Awarded NIST Grant for Developing Drug Testing Standards
October 31st 2024The grant will be part of a new collaborative scientific initiative to address the need for standards that define the desired performance of lateral flow immunoassay test strips to detect illicit drugs in tablets and powders.
